Alnylam and Arrowhead Form Collaboration and Licensing Agreement

January 2012
Biomedical Market Newsletter;1/7/2012, Vol. 21, p1
The article offers information on a collaboration and joint licensing agreement between Alnylam Pharmaceuticals Inc. and Arrowhead Research Corp. In this collaboration, Alnylam Pharmaceuticals, a RNAi therapeutics company, has provided license to Arrowhead Researc under its intellectual property for discovery, development and commercialization of an RNAi therapeutic against hepatitis B virus, in turn Arrowhead will receive payments from sales of licensed product.


Related Articles

  • The Medicines Company Licenses Alnylam's RNAi Programme Targeting PCSK9. Cartwright, Heather // PharmaDeals Review;2013, Vol. 2013 Issue 2, p16 

    The article focuses on the license received by Alnylam Pharmaceuticals Inc. from The Medicines Co. (TMC) for Alnylam's ALN-PCS RNAi therapeutic programme which will target proprotein convertase subtilisin/kexin type 9 (PCSK9). It states that the programme aims to treat hypercholesterolaemia. It...

  • Arrowhead Releases White Paper on Hepatitis B Virus and Potential RNAi Treatment.  // Biomedical Market Newsletter;3/7/2012, Vol. 21, p1 

    The article reports that Arrowhead Research Corp. has released a white paper related to the health problems associated with hepatitis B virus (HBV) and Dynamic Polyconjugate enabled RNA interference treatment used for treating HBV infected patients. Christopher Anzalone, President, the company,...

  • Arrowhead Hits Target In Hepatitis B Drug Trial. REEVES, AMY // Investors Business Daily;9/25/2015, p1 

    Beleaguered biotech stock Arrowhead Research (ARWR) gapped up sharply Thursday morning after the company reported positive midstage trial data on its hepatitis B drug candidate. Arrowhead kicked off its analyst day by releasing top-line data from its phase-two trial of its drug ARC-520 in...

  • Alnylam Scores Big on Its Phase I Data for ALN-TTRsc. Powers, Marie // BioWorld Today;7/12/2013, Vol. 24 Issue 132, p1 

    The article cites the findings for ALN-TTRsc, a subcutaneously administered RNAi therapy developed by Cambridge, Massachusetts-based Alnylam Pharmaceuticals Inc. for targeting transthyretin (TTR) in TTR-mediated amyloidosis. A phase I study found that ALN-TTRsc has achieved knockdown of serum...

  • Alnylam Reports Positive Preliminary Clinical Results for ALN-PCS, an RNAi Therapeutic Targeting PCSK9 for the Treatment of Severe Hypercholesterolemia.  // Biomedical Market Newsletter;1/7/2012, Vol. 21, p1 

    The article offers information related to an announcement made by Alnylam Pharmaceuticals Inc. regarding receiving positive preliminary results from its ongoing clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia. The primary objective...

  • Alnylam to Webcast Presentation at the Newsmakers in the Biotech Industry 2011 Conference.  // Biomedical Market Newsletter;10/26/2011, Vol. 21, p899 

    The article reports on the announcement of RNA interference (RNAi) therapeutics company Alnylam Pharmaceuticals Inc. that it will be presenting its company overview at the Newsmakers in the Biotech Industry 2011 Conference at the The Millennium Broadway Hotel in New York City. The presentations...

  • Alnylam to Webcast Presentation at the Seventh Annual JMP Securities Healthcare Conference.  // Biomedical Market Newsletter;7/7/2012, Vol. 21, p1 

    The article reports that Alnylam Pharmaceuticals Inc. will present a company overview at the Seventh Annual JMP Securities Healthcare Conference to be held at the Peninsula New York on July 12 2012. It states that Alnylam is a biopharmaceutical company which develops novel therapeutics based on...

  • Alnylam Presents New Data from its Conjugate Delivery Platform, Enabling.  // Biomedical Market Newsletter;8/7/2012, Vol. 21, p1 

    The article informs that data from the study of the GalNAc-conjugate siRNA programs for the systemic delivery of RNAi therapeutics by Alnylam Pharmaceuticals Inc. is presented at the XX International Roundtable on Nucleosides, Nucleotides and Nucleic Acids being held in Montreal, Canada from...

  • Alnylam Pharmaceuticals Grants InterfeRx(tm) Intellectual Property License to Sylentis for Development and Commercialization of RNAi Therapeutics.  // Biomedical Market Newsletter;11/21/2011, Vol. 21, p447 

    The article reports on the InterfeRx intellectual property license being granted by Alnylam Pharmaceuticals Inc. to Sylentis SA for development and commercialization of RNA interference (RNAi) therapeutics. It notes that Alnylam would receive payments and royalties on sales of products covered...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics